Advances in cancer vaccines for immunotherapy of prostate cancer.
10.11817/j.issn.1672-7347.2023.220034
- Author:
Tongtong JIN
1
;
Chuan ZHOU
2
;
Lei ZHAO
3
;
Xu DONG
3
;
Fenghai ZHOU
4
Author Information
1. First School of Clinical Medicine, Lanzhou University, Lanzhou 730000. Jinttlzu@163.com.
2. First School of Clinical Medicine, Lanzhou University, Lanzhou 730000.
3. Department of Urology, Gansu Provincial People's Hospital, Lanzhou 730000, China.
4. First School of Clinical Medicine, Lanzhou University, Lanzhou 730000. Zhoufengh@163.com.
- Publication Type:Journal Article
- Keywords:
Sipuleucel-T;
cancer vaccines;
immunotherapy;
prostate cancer
- MeSH:
Aged;
Humans;
Male;
Cancer Vaccines/therapeutic use*;
Immunotherapy;
Prostate/pathology*;
Prostatic Neoplasms/pathology*;
Tissue Extracts/therapeutic use*
- From:
Journal of Central South University(Medical Sciences)
2023;48(1):148-156
- CountryChina
- Language:English
-
Abstract:
Prostate cancer is currently one of the most common malignancies that endanger the lives and health of elderly men. In recent years, immunotherapy, which exploits the activation of anti-cancer host immune cells to accomplish tumor-killing effects, has emerged as a new study avenue in the treatment of prostate cancer. As an important component of immunotherapy, cancer vaccines have a unique position in the precision treatment of malignant tumors. Monocyte cell vaccines, dendritic cell vaccines, viral vaccines, peptide vaccines, and DNA/mRNA vaccines are the most often used prostate cancer vaccines. Among them, Sipuleucel-T, as a monocyte cell-based cancer vaccine, is the only FDA-approved therapeutic vaccine for prostate cancer, and has a unique position and role in advancing the development of immunotherapy for prostate cancer. However, due to its own limitations, Sipuleucel-T has not been widely adopted. Meanwhile, owing to the complexity of immunotherapy and the specificity of prostate cancer, the remaining prostate cancer vaccines have not shown good clinical benefit in large randomized phase II and phase III trials, and further in-depth studies are still needed.
